Denali Therapeutics DNLI
$18.45 +$0.25 (+1.37%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $18.45 0.00%
Open$17.97
Prev close$18.20
Day range$17.92 – $18.85
Volume2.63M
Market cap$2.96B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$17.78M
Operating profit-$126.75M+7.8% YoY
Net profit$70.13M+155.3% YoY
Diluted EPS$0.37+150.0% YoY
Free cash flow-$125.65M-18.6% YoY
Operating cash flow-$117.44M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin98.9%
Operating margin-2,488.1%
Net margin-1,470.5%
Return on equity-33.9%
Return on assets-27.2%
Return on invested capital-35.1%
Current ratio6.21
Liabilities / assets26.2%
Cash & investments$516.20M
Total debt$19.28M
Net cash (debt)$496.92M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $17.78M | $3.60M | – | $0.00 | $0.00 |
| Total Operating Revenue | $17.78M | $3.60M | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $192,000.00 | $93,000.00 | – | – | – |
| Gross Profit | $17.59M | $3.51M | – | – | – |
| Operating Expense | $144.34M | $134.05M | $137.36M | $555.34M | $137.37M |
| Selling and Admin Expenses | $37.49M | $36.28M | $33.51M | $136.56M | $39.46M |
| Research & Development | $106.10M | $97.02M | $103.85M | $418.78M | $97.91M |
| Depreciation & Amortization & Depletion | $750,000.00 | $750,000.00 | – | – | – |
| -Depreciation & Amortization | $750,000.00 | $750,000.00 | – | – | – |
| Operating Profit | -$126.75M | -$130.54M | -$137.36M | -$555.34M | -$137.37M |
| Net Non-Operating Interest Income (Expense) | $2.88M | $2.99M | $8.91M | $42.90M | $8.92M |
| Non-Operating Interest Income | $2.88M | $2.99M | $8.91M | $42.90M | $8.92M |
| Other Income (Expense) | $194.00M | – | – | – | – |
| Special Income (Charges) | $194.00M | – | – | $0.00 | $0.00 |
| -Gain on Sale of Property/Plant/Equipment | $194.00M | – | – | – | – |
| Pretax Profit | $70.13M | -$127.55M | -$128.45M | -$512.44M | -$128.45M |
| Net Profit | $70.13M | -$127.55M | -$128.45M | -$512.54M | -$128.55M |
| Profit from Continuing Operations | $70.13M | -$127.55M | -$128.45M | -$512.54M | -$128.55M |
| Net Income to Parent Company | $70.13M | -$127.55M | -$128.45M | -$512.54M | -$128.55M |
| Net Income to Common Stockholders | $70.13M | -$127.55M | -$128.45M | -$512.54M | -$128.55M |
| Basic EPS | $0.37 | -$0.68 | -$0.69 | -$2.97 | -$0.73 |
| Diluted EPS | $0.37 | -$0.68 | -$0.69 | -$2.97 | -$0.73 |
| -General & Admin Expense | – | $36.28M | $33.51M | $136.56M | $39.46M |
| -Gain on Sale Of Business | – | – | – | $0.00 | $0.00 |
| Tax | – | – | – | $102,000.00 | – |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.26B | $1.16B | $1.27B | $1.14B | $1.14B |
| Total Current Assets | $591.71M | $753.93M | $1.02B | $900.66M | $900.66M |
| Cash and Cash Equivalents & Short-Term Investments | $516.20M | $710.47M | $987.68M | $867.88M | $867.88M |
| -Cash and Cash Equivalents | $102.87M | $201.53M | $387.63M | $205.33M | $205.33M |
| -Short Term Investments | $413.33M | $508.94M | $600.06M | $662.55M | $662.55M |
| Receivables | $18.88M | $3.93M | – | $2.18M | $2.18M |
| -Accounts Receivable | $18.88M | $3.93M | – | $2.18M | $2.18M |
| Inventory | $26.28M | $4.14M | – | – | – |
| Other Current Assets | $30.36M | $35.39M | $35.07M | – | – |
| Total Non-Current Assets | $664.33M | $404.03M | $243.27M | $244.20M | $244.20M |
| Net PPE | $109.30M | $113.42M | $117.27M | $119.94M | $119.94M |
| -Gross PPE | $109.30M | $113.42M | $117.27M | $182.83M | $182.83M |
| Investments and Advances | $491.38M | $229.53M | $63.79M | $98.32M | $98.32M |
| -Available for Sale Securities | $491.38M | – | – | – | – |
| Goodwill and Other Intangible Assets | $34.50M | $35.25M | $36.00M | – | – |
| Other Non-Current Assets | $29.15M | $25.83M | $26.22M | $25.94M | $25.94M |
| Total Liabilities | $329.65M | $322.78M | $339.93M | $131.09M | $131.09M |
| Total Current Liabilities | $95.26M | $90.08M | $110.16M | $98.35M | $98.35M |
| Payables | $13.70M | $11.81M | $40.38M | $3.33M | $3.33M |
| -Accounts Payable | $13.70M | $11.81M | $40.38M | $3.33M | $3.33M |
| Current Accrued Expenses | $33.93M | $34.70M | $35.58M | $32.20M | $32.20M |
| Short-Term Debt and Capital Lease Obligation | $10.51M | $10.18M | $9.86M | $9.55M | $9.55M |
| -Current Capital Lease Obligation | $10.51M | $10.18M | $9.86M | $9.55M | $9.55M |
| Current Deferred Liabilities | $16.42M | $19.98M | $15.12M | $21.10M | $21.10M |
| Total Non-Current Liabilities | $234.39M | $232.69M | $229.77M | $32.74M | $32.74M |
| Long Term Debt and Capital Lease Obligation | $19.28M | $22.03M | $24.68M | $27.21M | $27.21M |
| -Long Term Capital Lease Obligation | $19.28M | $22.03M | $24.68M | $27.21M | $27.21M |
| Other Non-Current Liabilities | $215.11M | $5.48M | $5.51M | $5.53M | $5.53M |
| Total Equity | $926.39M | $835.18M | $926.10M | $1.01B | $1.01B |
| Stockholders' Equity | $926.39M | $835.18M | $926.10M | $1.01B | $1.01B |
| Capital Stock | $1.93M | $1.92M | $1.91M | $1.89M | $1.89M |
| -Common Stock | $1.93M | $1.92M | $1.91M | $1.89M | $1.89M |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $3.17B | $3.14B | $3.10B | $3.06B | $3.06B |
| Retained Earnings | -$2.24B | -$2.31B | -$2.18B | -$2.05B | -$2.05B |
| Gains/Losses Not Affecting Retained Earnings | -$6.36M | -$1.97M | -$682,000.00 | $682,000.00 | $682,000.00 |
| Non-Current Deferred Liabilities | – | $205.19M | $199.58M | – | – |
| Prepaid Assets | – | – | – | $30.60M | $30.60M |
| -Accumulated Depreciation | – | – | – | -$62.90M | -$62.90M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$117.44M | -$97.00M | -$131.20M | -$412.60M | -$98.54M |
| Net cash flow from continuing operations | -$117.44M | -$97.00M | -$131.20M | -$412.60M | -$98.54M |
| Net Income from Continuing Operations | $70.13M | -$127.55M | -$128.45M | -$512.54M | -$128.55M |
| Depreciation & Depletion & Amortization | $4.49M | $4.48M | $3.76M | $14.81M | $3.78M |
| Other Non-Cash Items | $3.51M | $4.22M | -$850,000.00 | -$4.40M | -$1.10M |
| Change in Working Capital | -$23.41M | $382,000.00 | -$27.50M | $149,000.00 | $5.02M |
| -Change in Receivables | -$14.96M | – | – | – | – |
| -Change in Inventory | -$22.14M | – | – | – | – |
| -Change in Prepaid Assets | $5.14M | -$322,000.00 | -$2.29M | -$540,000.00 | $1.75M |
| -Change in Payables and Accrued Expense | $15.42M | $3.52M | -$18.52M | -$7.06M | $9.32M |
| -Change in Other Current Assets | -$3.32M | $396,000.00 | -$700,000.00 | $772,000.00 | -$533,000.00 |
| -Change In Other Working Capital | -$3.56M | $4.86M | -$5.99M | $6.97M | -$5.52M |
| Net cash flow from investing | $16.19M | -$104.08M | $94.46M | $255.28M | $20.77M |
| Net Cash Flow from Continuing Investing Activities | $16.19M | -$104.08M | $94.46M | $255.28M | $20.77M |
| Net PPE Purchase and Sale | -$1.01M | -$805,000.00 | -$2.47M | -$9.50M | -$1.52M |
| Net Intangibles Purchase and Sale | -$7.20M | – | – | – | – |
| Net Investment Purchase and Sale | -$169.60M | -$74.47M | $96.93M | $264.78M | $22.29M |
| Financing Cash Flow | $2.59M | $14.98M | $219.04M | $189.22M | $192.13M |
| Net Cash Flow from Continuing Financing Activities | $2.59M | $14.98M | $219.04M | $189.22M | $192.13M |
| Net Issuance Payments Of Debt | -$22,000.00 | -$21,000.00 | -$17,000.00 | -$8.17M | -$16,000.00 |
| Proceeds from Stock Option Exercised | $2.61M | $15.01M | $19.06M | $8.46M | $3.22M |
| Net Other Financing Charges | $0.00 | $0.00 | $200.00M | -$324,000.00 | – |
| Ending Cash Balance | $105.98M | $204.64M | $390.73M | $208.43M | $208.43M |
| Net Change in Cash | -$98.66M | -$186.10M | $182.30M | $31.90M | $114.36M |
| Beginning Cash Balance | $204.64M | $390.73M | $208.43M | $176.54M | $94.07M |
| Free Cash Flow | -$125.65M | -$126.61M | -$133.67M | -$422.10M | -$100.06M |
| -Change in Other Current Liabilities | – | – | – | $0.00 | – |
| Net Common Stock Issuance | – | – | – | $189.25M | $189.25M |
No comments yet — be the first to weigh in on DNLI.
Sign in to join the discussion.